Keywords: CHP; Chronic hypersensitive pneumonia; DILD; Drug-induced interstitial lung disease; IIP; Idiopathic interstitial pneumonia; ILD; Interstitial lung disease; IPF; Idiopathic pulmonary fibrosis; PCV13; 13-valent pneumococcal conjugated vaccine; PPSV23; 23-v
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Otitis media burden; Tympanometry; Low-resource countries; Cameroonian children; PCV13;
Keywords: Vaccination; Immunization; Coverage; Parent-report; Accuracy; PHANTIM; Primary Health Activity Network & Timely Information Management; DTaP-IPV-Hib; diphtheria-tetanus-acellular pertussis-polio-Haemophilus influenzae type b; MMR; measles-mumps-rubella; M
Keywords: Timeliness; Multi-cohort Markov modelling; Uptake; PCV13; Elderly; Pneumococcal; Economic evaluation; Pneumonia; Adult vaccination;
Keywords: pneumococcal conjugate vaccine; pneumococcal polysaccharide vaccine; immunization information system; sickle cell disease; ACIP; Advisory Committee on Immunization Practices; LBF; Live birth file; MCIR; Michigan Care Improvement Registry; MCV4; 4-Valent m
Keywords: Community pharmacy; Pharmacist; Immunization; Vaccine; IIS; Immunization Information Systems; ACIP; Advisory Committee on Immunization Practices; APhA; American Pharmacists Association; CDC; Centers for Disease Control and Prevention; CMS; Centers for Med
Keywords: Neonatal intensive care; Hospital discharge; Peer support; Parent navigator; Parent depression; Parent stress; NICU; neonatal intensive care unit; PN; parent navigation; PNs; parent navigators; ED; emergency department; GPS; Giving Parents Support; DTaP;
Keywords: Rheumatoid arthritis; Immunosuppressive therapy; 13-valent pneumococcal conjugate vaccine; Immunogenicity; Antibody persistence; RA; Rheumatoid arthritis patients; HC; Healthy control subjects; PnPS; pneumococcal polysaccharides; PCV13; 13-valent pneumoco
Keywords: PPSV23; 23-valent pneumococcal polysaccharide vaccine; PCV13; 13-valent pneumococcal conjugate vaccine; influenzavaccine; seasonal influenza vaccine; COPD; chronic obstructive pulmonary disease; ADL; activities of daily living; OR; odds ratio; CI; confide
Keywords: HCPs; healthcare providers; VPDs; vaccine-preventable diseases; PCV13; 13-valent pneumococcal conjugate vaccine; Hib; Haemophilus influenzae type b; HBV; hepatitis B virus; DTaP; IPV-diphtheria, tetanus toxoid, acellular pertussis, and inactivated polio v
Keywords: Streptococcus pneumoniae; Vaccine; PCV13; PPSV23; Serotype replacement;
Keywords: AE; adverse event; CI; confidence interval; ELISA; enzyme-linked immunosorbent assay; GMC; geometric mean concentration; GMT; geometric mean titer; PCV7; 7-valent pneumococcal conjugate vaccine; PCV13; 13-valent pneumococcal conjugate vaccine; PHiD-CV; pn
Keywords: Pneumococcal conjugate vaccine; Cost-effectiveness; Mongolia; Vaccine; Budget impact; PCV13; AMC; advance market commitment; AOM; acute otitis media; CFR; case-fatality risk; DALY; disability-adjusted life year; GDP; gross domestic product; GNI; gross nat
Keywords: Pneumococcal conjugate vaccine; PCV13; Streptococcus pneumoniae; HIV; Kidney; Lung;
Keywords: health care service utilization; immunization; infectious disease burden; LRI; Lower respiratory tract infection; NIP; National Immunization Plan; PCV; Pneumococcal conjugate vaccine; PCV7; 7-valent pneumococcal conjugate vaccine; PCV13; 13-valent pneumoc
Keywords: AOM; acute otitis media; CI; confidence interval; CRM; cross-reacting material 197; DT; diphtheria toxoid; DTaP; diphtheria, tetanus, acellular pertussis; DTwP; diphtheria, tetanus, whole-cell pertussis; dPly; detoxified pneumolysin; EPA; exotoxin A of Ps
Keywords: Community-acquired pneumonia; Invasive pneumococcal disease; Pneumococcal conjugate vaccine; Streptococcus pneumoniae; ABC; Active Bacterial Core surveillance; ACIP; Advisory Committee on Immunization Practices; BAC; bacteremic; CAP; community acquired pn
Keywords: parapneumonic effusion; corticosteroids; corticoids; pneumonia; CAP; Community-acquired pneumonia; CRP; C-reactive protein; DXM; Dexamethasone; PCV13; Pneumococcal conjugate vaccine; SaO2; Oxygen saturation; VATS; Video-assisted thoracic surgery;
Keywords: Rheumatoid arthritis; Conjugated pneumococcal vaccine; PCV13; Etanercept; Protective antibody level;
Keywords: ACIP; Advisory Committee on Immunization Practices; CAPiTA; Community-Acquired Pneumonia Immunization Trial in Adults; CPS; capsular polysaccharide; IPD; invasive pneumococcal disease; NIPP; noninvasive pneumococcal pneumonia; PCV7; 7-valent pneumococcal
Keywords: DTaP; Polio; Hib; Hepatitis B; Hexavalent; Vaccine; Safety; Immunogenicity; AE; adverse event(s); CI; confidence interval; D; diphtheria toxoid; DTaP5; diphtheria, tetanus, acellular pertussis (5-component) vaccine (Daptacelâ¢); DTPa3-HB-IPV/Hib; diphthe
Keywords: Streptococcus pneumoniae; Multiple serotype carriage; Co-colonization; Pneumococcal conjugate vaccine; PCV13; Microarray;
Keywords: Idiopathic nephrotic syndrome (NS); Immunization; Streptococcus pneumoniae; 13-valent pneumococcal conjugate vaccine (PCV13); Vaccine; Enzyme-linked immunosorbent assay (ELISA); AIM; alternative immunosuppressive medication; CI; confidence interval; ELISA
Keywords: IS; immunosuppressive; AD; autoimmune disease; HIV; human immunodeficiency virus; PCP; pneumocystis pneumonia; VE; vaccine efficacy; ANCA; antineutrophil cytoplasmatic antibodies; SLE; systemic lupus erythematosus; ASIA; autoimmune inflammatory syndrome i
Keywords: Pneumococcal polysaccharide vaccine; 23vPPV; hyporesponsiveness; memory BÂ cell; opsonophagocytosis; antibody; CPS; Cell-wall polysaccharide; FiPP; Fiji Pneumococcal Project; MOPA; Multiplexed opsonophagocytic assay; OI; Opsonization index; OPA; Opsonopha
Keywords: Pneumococcal conjugate vaccine; Vaccine clinical evaluation; Immunization; Immunogenicity; AE; adverse event; CI; confidence interval; ELISA; enzyme-linked immunosorbent assay; GMC; geometric mean concentration; Ig; immunoglobulin; IPD; invasive pneumococ
Keywords: AE; adverse event; CAP; community-acquired pneumonia; GMFR; geometric mean fold rise; GMT; geometric mean titer; IPD; invasive pneumococcal disease; OPA; opsonophagocytic activity; PCV13; 13-valent pneumococcal conjugate vaccine; PPSV23; 23-valent pneumoc
Keywords: Survival analysis; Cohort; Methodology; Vaccine effectiveness; Children; Pneumonia; Diarrhoea; PCV13; RV1; Pneumococcal disease;
Keywords: ARIa; cute respiratory infection; DSSd; emographic surveillance system; EPIe; xpanded program on immunization; GAVIg; lobal alliance for vaccines and immunization; IMCIi; ntegrated management of childhood illness; IPD; invasive pneumococcal disease; MEOm;
Keywords: PCVs; pneumococcal conjugate vaccines; PCV7; 7-valent pneumococcal conjugate vaccine; PCV10; 10-valent pneumococcal conjugate vaccine; PCV13; 13-valent pneumococcal conjugate vaccine; Pneumococcal conjugate vaccine; Streptococcus pneumoniae; Cost-effectiv
Keywords: ACIP; Advisory Committee on Immunization Practices; ADEM; acute disseminated encephalomyelitis; AE; adverse events; AIDP; acute inflammatory demyelinating polyradiculoneuropathy; AMAN; acute motor axonal neuropathy; AMSAN; acute motor and sensory neuropat
Keywords: Streptococcus pneumoniae; Serotyping; PCR; PCV7; PCV13;
Keywords: MIC; Minimum inhibitory concentration; PCV7; 7-valent pneumococcal conjugate vaccination; PCV13; 13-valent pneumococcal conjugate vaccination; PRSS-P; Pediatric Rhinosinusitis Symptom scale;
Keywords: PCV13; Streptococcus pneumoniae; Pneumococcal conjugate vaccine; Serotype replacement; Invasive pneumococcal disease; Prevnar 13;
Keywords: AE; adverse event; CI; confidence interval; CRM197; cross-reactive material 197; GMR; geometric mean ratio; GMT; geometric mean titer; IPD; invasive pneumococcal disease; LLOQ; lower limit of quantitation; LOD; limit of detection; OPA; opsonophagocytic ac
Keywords: ACIP; United States Advisory Committee on Immunization Practices; AE; adverse event; CI; confidence interval; CRM197; cross-reactive material 197; GMR; geometric mean ratio; GMT; geometric mean titer; OPA; opsonophagocytic activity; PCV; pneumococcal poly
Keywords: 2+1; PCV13; Immune response; Pediatric; Pneumococcal conjugate vaccine;
Keywords: Pneumonia; PCV7; PCV10; PCV13; Vaccines; Children
Keywords: Community-acquired pneumonia; Invasive pneumococcal disease; PCV13; Pneumococcal conjugate vaccine; Persistence of vaccine efficacy
Keywords: Socioeconomic status; PCV13; Pneumococcus; Pneumococcal vaccine; Vaccine effectiveness; Matched case-control
Evolution over time in the cost-effectiveness of pneumococcal conjugate vaccine (PCV13) in older Australians due to herd protection from infant vaccination
Keywords: PCV13; Pneumonia; Herd immunity; Immunization; Markov model; Evolution of serotype;
Immunogenicity and safety of measles-mumps-rubella vaccine at two different potency levels administered to healthy children aged 12-15â¯months: A phase III, randomized, non-inferiority trial
Keywords: MMR vaccine; Measles; Mumps; Rubella; Immunogenicity; Safety; AE; adverse event; ATP; according-to-protocol; CI; confidence interval; ELISA; enzyme-linked immunosorbent assay; GMC; geometric mean concentration; GMT; geometric mean titer; HAV; hepatitis A
Comparative incidence dynamics and serotypes of meningitis, bacteremic pneumonia and other-IPD in young children in the PCV era: Insights from Israeli surveillance studies
Keywords: Pneumonia; IPD - invasive pneumococcal disease; PCV - pneumococcal conjugate vaccine; Dynamics; Children; Surveillance; IPD; invasive pneumococcal disease; PCV7; 7-valent pneumococcal conjugated vaccine; PCV13; 13-valent pneumococcal conjugated vaccin
Immunologic non-inferiority and safety of the investigational pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) 4-dose vial presentation compared to the licensed PHiD-CV 1-dose vial presentation in infants: A phase III
Keywords: Pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV); 1-dose vial presentation; 4-dose vial presentation; Immunologic non-inferiority; Safety; Infants; AE; adverse event; ATP; according-to-protocol; CI; confidence interva
Immunogenicity and safety of one or two doses of the quadrivalent meningococcal vaccine MenACWY-TT given alone or with the 13-valent pneumococcal conjugate vaccine in toddlers: A phase III, open-label, randomised study
Keywords: AE; adverse event; ATP; according-to-protocol; CI; confidence interval; ELISA; enzyme-linked immunosorbent assay; GMC; geometric mean concentration; GMT; geometric mean titre; hSBA; human complement serum bactericidal antibody assay; MenACWY-TT; quadrival
A toddler PCV booster dose following 3 infancy priming doses increases circulating serotype-specific IGG levels but does not increase protection against carriage
Keywords: Pneumococcal conjugate vaccines; PCV; Carriage; Serologic response; Booster; Vaccine schedule; Infants; Toddlers; 7VT+6A; pneumococcal serotypes included in PCV7 and serotype 6A; MCHCs; Mother-and-Child Health Centers; MOPA; multiplexed opsonophagocytosis
Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults â¥50â¯years of age: A randomized trial
Keywords: VZV; varicella-zoster virus; HZ; herpes zoster; PHN; postherpetic neuralgia; CDC; United States Centers for Disease Control and Prevention; YOA; years of age; ZVL; zoster vaccine live; RZV; adjuvanted recombinant zoster vaccine; PPSV23; 23-valent pneumoco
Serotype distribution, antibiotic resistance patterns and molecular characteristics of serogroup 6 Streptococcus pneumoniae isolates collected from Chinese children before the introduction of PCV13
Keywords: Streptococcus pneumoniae; Serotype; Antibiotic resistance; PCV13; Children;
Ãvaluation de l'immunogénicité du vaccin pneumococcique conjugué 13-valent chez des patients atteints de polyarthrite rhumatoïde traités par étanercept
Keywords: Polyarthrite rhumatoïde; Vaccin pneumococcique conjugué; PCV13; Ãtanercept; Taux d'anticorps protecteurs;
Functional immune responses to 11 non-PCV13 serotypes after immunization with a 23-valent pneumococcal polysaccharide vaccine in older adults
Keywords: PPSV23; 23-valent pneumococcal polysaccharide vaccine; IPD; invasive pneumococcal diseases; PCV13; 13-valent pneumococcal conjugate vaccine; OPA; opsonophagocytic assay; MOPA; multiplexed OPA; OBB; opsonization buffer B; BRC; Baby rabbit complement; THY;